TL;DR: 🟢 Positive — tranexamic acid significantly reduced 5-day treatment failure (6.3% vs 13.3%, P=0.006) in cirrhosis-associated upper GI bleeding, contrasting with the broader HALT-IT trial's null result.
1. Publication
- Title: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis: A randomized controlled trial
- Acronym: None assigned
- Year & Journal: Hepatology, published March 5, 2024 (80(2):376-388)
- Citation: Kumar M, Venishetty S, Jindal A, et al. Hepatology. 2024;80(2):376-388. doi:10.1097/HEP.0000000000000817
2. Context & Rationale
Background: Patients with Child-Turcotte-Pugh (CTP) class B/C cirrhosis and upper GI bleeding (UGIB) have both systemic and localized (esophageal/gastric mucosal) fibrinolysis. The large HALT-IT trial (Lancet 2020) found no benefit (and possible thrombotic harm) from tranexamic acid (TXA) in general acute GI bleeding, but did not specifically enrich for cirrhosis with its distinct fibrinolytic pathophysiology.
Research Question/Hypothesis: In patients with advanced cirrhosis (CTP B/C) presenting with UGIB, does tranexamic acid reduce 5-day treatment failure compared with placebo?
3. Design & Methods
- Study Type: Randomized, placebo-controlled trial
- Population: 600 patients with advanced liver cirrhosis (CTP B or C) presenting with UGIB
- Intervention: Tranexamic acid (n=300)
- Comparator: Placebo (n=300)
- Statistical Power & Follow-Up: Primary: proportion developing 5-day treatment failure. Secondary: rebleeding after day 5 to 6 weeks.
4. Key Results
600 patients randomized.
Outcome | Tranexamic Acid | Placebo | p-value | Notes |
5-day treatment failure (primary) | 19/300 (6.3%) | 40/300 (13.3%) | 0.006 | Significant reduction with TXA |
Rebleeding, day 5 to 6 weeks | Reduced | — | — | Also significantly reduced (per abstract conclusion) |
Note: A subsequent 2025 meta-analysis noted that when this and similar cirrhosis-specific studies are analyzed together, the rebleeding effect became non-significant (RR 0.83, 95% CI 0.67-1.03, P=0.07) — indicating this individual trial's effect, while itself statistically significant, should be interpreted alongside the broader, somewhat more modest pooled evidence.
5. Internal Validity Assessment
Adequately powered (600-patient), randomized, placebo-controlled trial with a clear, statistically significant primary result. Overall: Moderate-to-strong — clean, significant primary result in a population enriched for the specific pathophysiology (cirrhosis-associated fibrinolysis) TXA targets; however, a subsequent letter to the editor raised methodological questions (addressed in a published author reply), and pooled meta-analytic data suggest the rebleeding-specific effect may be less robust than this single trial's point estimate.
6. External Validity Assessment
Indian population with advanced cirrhosis (CTP B/C) and UGIB — relevant to similar high-burden cirrhosis populations, particularly in regions with high rates of variceal bleeding.
7. Strengths & Limitations
Strengths: Large (600-patient), adequately powered, placebo-controlled design; specifically enriches for the cirrhosis population with the distinct fibrinolytic pathophysiology TXA is mechanistically suited to address, in contrast to HALT-IT's broader, unselected GI bleeding population.
Limitations: Single-country trial; a published letter to the editor and author reply indicate some methodological questions were raised post-publication; subsequent meta-analytic pooling suggests the rebleeding-specific benefit may be less robust when combined with other data.
8. Interpretation & Practice Impact
Supports considering tranexamic acid specifically in cirrhosis-associated UGIB (CTP B/C), a population with a plausible, distinct fibrinolytic mechanism — contrasting with the broader HALT-IT trial's null/harm signal in unselected GI bleeding, illustrating that population selection (targeting the specific pathophysiology) may matter for TXA's efficacy in GI bleeding.
9. Controversies & Subsequent Evidence
A "Tranexamic acid in variceal bleeding revisited" commentary and a published letter-to-the-editor/reply exchange directly engage with this trial's methodology and interpretation. A 2025 systematic review/meta-analysis notes that when this cirrhosis-specific evidence is pooled with other similar studies, the rebleeding-prevention effect attenuates to non-significance (RR 0.83, P=0.07) — an important nuance suggesting this individual trial's positive result should be read as part of a still-developing, not yet fully settled evidence base specifically for cirrhosis-associated GI bleeding.
10. Summary & Executive Takeaway
Summary: This randomized, placebo-controlled trial enrolled 600 patients with advanced cirrhosis (CTP B/C) and upper GI bleeding to tranexamic acid or placebo. TXA significantly reduced 5-day treatment failure (6.3% vs 13.3%, P=0.006) and rebleeding through 6 weeks.
Overall Takeaway: Tranexamic acid significantly reduces treatment failure and rebleeding in cirrhosis-associated upper GI bleeding — contrasting with the broader HALT-IT trial's null/harm finding in unselected GI bleeding, and suggesting population selection based on the specific fibrinolytic pathophysiology of cirrhosis may be key to TXA's efficacy, though subsequent pooled meta-analysis suggests some attenuation of the rebleeding-specific effect when combined with other cirrhosis-focused data.
11. Bibliography
- HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute GI bleeding. Lancet. 2020;395(10241):1927-1936.
- Raman KP, Patch D. Tranexamic acid in variceal bleeding revisited [commentary]. Hepatology. 2024;80(2):257-259.